Investigational drug · Phase 3
Anitocabtagene Autoleucel
Also called: CART-ddBCMA
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Multiple Myeloma, Newly Diagnosed Multiple Myeloma.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
8
Any phase or sponsor naming "Anitocabtagene Autoleucel"
First trial start
2022
Jul 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Anitocabtagene Autoleucel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Multiple Myeloma
- Newly Diagnosed Multiple Myeloma
Approved drugs for the same conditions: Multiple myeloma · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "Anitocabtagene Autoleucel" as an intervention, largest first.
- Long-Term Follow-Up Study After Gene-Modified Cell Treatment in Kite StudiesEnrolling by invitation
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT05041309 · 1,500 participants (planned) · Start Dec 15, 2021 · Primary completion Dec 2040
Drug: Axicabtagene Ciloleucel; Brexucabtagene Autoleucel and 9 more · For: Solid and Hematological Malignancies; Autoimmune Diseases
Sites: Gilbert, Arizona; Duarte, California; La Jolla, California · 91 sites in all
- To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple MyelomaPivotal-lookingNot yet recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07903506 · 750 participants (planned) · Start Feb 2027 · Primary completion Mar 2039
Drug: Anitocabtagene Autoleucel; Isatuximab and 6 more · For: Newly Diagnosed Multiple Myeloma
- A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple MyelomaPivotal-lookingNot yet recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT07887672 · 600 participants (planned) · Start Jan 2027 · Primary completion Feb 2042
Drug: Anitocabtagene autoleucel; Daratumumab and 5 more · For: Newly Diagnosed Multiple Myeloma
- A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple MyelomaPivotal-lookingActive, not recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT06413498 · 452 participants · Start Aug 23, 2024 · Primary completion Jul 2028
Drug: Anitocabtagene Autoleucel; Cyclophosphamide and 6 more · For: Multiple Myeloma
Sites: Gilbert, Arizona; Duarte, California; Los Angeles, California · 117 sites in all
- Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Active, not recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT05396885 · 136 participants · Start Jul 15, 2022 · Primary completion Dec 2026
Drug: anitocabtagene-autoleucel · For: Multiple Myeloma
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Denver, Colorado · 18 sites in all
- Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple MyelomaActive, not recruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT04155749 · 40 participants · Start Dec 23, 2019 · Primary completion Oct 3, 2024
Drug: anitocabtagene-autoleucel · For: Relapsed and Refractory Multiple Myeloma
Sites: Chicago, Illinois; Boston, Massachusetts; Milwaukee, Wisconsin · 4 sites in all
PETHEMA FoundationAcademic, hospital or other
NCT07045909 · 30 participants (planned) · Start Jun 30, 2025 · Primary completion Mar 31, 2028
Drug: Daratumumab; Isatuximab and 5 more · For: De Novo Multiple Myeloma; Anitocabtagene Autoleucel
Sites: Badalona, Spain; Barcelona, Spain; Madrid, Spain · 10 sites in all
- Study of Anitocabtagene Autoleucel in Participants With Non-Oncology Plasma Cell-Related DiseasesRecruiting
Kite, A Gilead CompanyGilead Sciences (GILD)
NCT06626919 · 30 participants (planned) · Start Apr 30, 2025 · Primary completion Oct 2028
Drug: anito-cel; Cyclophosphamide and 1 more · For: Muscular Diseases; Neuromuscular Manifestations; Autoimmune and 4 more
Sites: Los Angeles, California; Orange, California; Palo Alto, California · 14 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Phase 1 study of CART-ddBCMA for the treatment of subjects with relapsed and refractory multiple myeloma.
Frigault MJ, Bishop MR, Rosenblatt J, et al. · Blood Adv 2023
- Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain.
Buonato JM, Edwards JP, Zaritskaya L, et al. · Mol Cancer Ther 2022
Also in development for Multiple Myeloma
- EtentamigABBV-383, TNB-383BPhase 38 trials
AbbVie · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma, Amyloid Light Chain (AL) Amyloidosis
- BMS-986348CC-92480, mezigdomidePhase 37 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- GR1803Velinotamig specified specified days., CLN-803Phase 37 trials
Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Multiple Myeloma, Immune Thrombocytopenia (ITP), Warm Autoimmune Hemolytic Anemia (WAIHA)
- JNJ-79635322Ramantamig, BCMAxGPRC5DxCD3Phase 37 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- Cilta-celJNJ-68284528Phase 36 trials
Johnson & Johnson (Janssen) · Multiple Myeloma
- CevostamabRO7187797Phase 34 trials
Roche (Genentech) · Multiple Myeloma
- IBI3003Phase 34 trials
Innovent Biologics (Suzhou) Co. Ltd. · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma
- Arlocabtagene AutoleucelBMS-986393, GPRC5D CAR T cellsPhase 32 trials
Bristol Myers Squibb · Multiple Myeloma, Relapsed or Refractory Multiple Myeloma (RRMM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Gilead Sciences.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.